A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586)

Lung Cancer

Volumn 25, Issue 3, 1999, Pages 199-206

  Tester, William J ^a   Kim, Kyung Mann ^b   Krigel, Robert L ^a,h   Bonomi, Philip D ^c   Glick, John H ^d   Asbury, Robert F ^e   Kirkwood, John M ^f   Blum, Ronald H ^g   Schiller, Joan H ^b  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e The Genesee Hospital   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^g ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^h FOX CHASE CANCER CENTER   (United States)

Author keywords

Beta interferon; Interleukin 2; Non small cell lung cancer

Indexed keywords

BETA INTERFERON; CISPLATIN; ETOPOSIDE; INDOMETACIN; INTERLEUKIN 2; MITOMYCIN; PARACETAMOL; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; EXFOLIATIVE DERMATITIS; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SURVIVAL RATE; THROMBOSIS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-BETA; INTERLEUKIN-2; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032883839     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00054-9     Document Type: Article

References (26)

1. Souquet P.J., Chauvin F., Boissel J.P., Cellerino R., Cormier Y., Ganz P.A. et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 342(8862):1993;19-21.
2. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J. Clin. Oncol. 11(10):1993;1866-1872.
3. Lotze MT. Interleukin-2: Basic principles. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic Therapy of Cancer. Philadelphia: JB Lippincott, 1991: 123-141.
4. SER, and γ interferons on human cell lines of various histogenesis. Cancer Res. 46:1986;483-488.
5. Rosenberg S.A., Schwarz S.L., Spiess P.J. Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. J. Natl. Cancer Inst. 80:1988;1393.
6. Brunda M.J., Bellantoni D., Sulich V. In vivo antitumor activity of combinations of interferon-alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer. 40:1987;365-371.
7. van de Griend R.J., Ronteltap C.P., Gravekamp C., Monnikendam D., Bolhuis R.L. Interferon-β and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones. J. Immunol. 136(5):1986;1700-1707.
8. Cameron R.B., McIntosh J.K., Rosenberg S.A. Synergistic antitumor effects of combination chemotherapy with recombinant interleukin-2 and recombinant hybrid interferon in the treatment of established immune hepatic metastases. Cancer Res. 48:1988;5810-5817.
9. Iigo M., Sakurai M., Tamura T., Saijo N., Hoshi A. In vivo antitumor activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res. 48:1988;260-264.
10. Bernstein Z.P., Goldrosen M.H., Vaickus L., Friedman N., Watanabe H., Rahman R. et al. Interleukin-2 with ex vivo activated killer cells: therapy of advanced non-small-cell lung cancer. J. Immunother. 10(5):1991;383-387.
11. Ardizzoni A., Bonavia M., Viale M., Baldini E., Mereu C., Verna A. et al. Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer. 73(5):1994;1353-1360.
12. Larrouturou P, Taugourdeau MC, Brossel C, Bedin A, Rebischung JL. Continuous infusion of low dose of interleukin-2 as therapy for patients with non small cell lung cancer: pharmaceutical aspects (sterile isolator) and clinical results (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1994;13:A1193.
13. Lissoni P., Meregalli S., Paolorossi F., Fossati V., Frigerio F., Tancini G. et al. A randomized study of immunotherapy with low-dose IL-2 plus melatonin vs chemotherapy with cisplatin and VP-16 as a first line therapy in advanced non-small cell lung cancer (meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13:1994;A1070.
14. Krigel RL, Padavic-Shaller, Rudolph AR, Litwin S, Konrad M, Bradley EC, et al. A phase I study of recombinant interleukin 2 plus recombinant β-interferon. Cancer Res 1988;48:3875-3881.
15. Finkelstein DM, Delgado, F. Analysis of EST 1585. Technical Report: Division of Biostatistics and Epidemiology. Boston: Dana-Farber Cancer Institute, 1990.
16. Bonomi P., Finkelstein D., Chang A. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am. J. Clin. Oncol. 17(3):1994;215-217.
17. Kim K, Boucher H, Crouse, C. Analysis of EST 1587; Phase II protocol for chemotherapy in metastatic non-small cell bronchogenic carcinoma. Technical Report 661E. Division of Biostatistics and Epidemiology. Boston: Dana-Farber Cancer Institute, 1992.
18. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 53:1985;457-481.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in consideration. Cancer Chemother. Rep. 50:1966;163-170.
21. Bunn P.A., Kelley K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 5:1998;1087-1100.
22. Schiller J.H., Storer B., Dreicer R., Rosenquist D., Frontiera M., Carbone P.P. Randomized Phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell lung cancer. J. Natl. Cancer Inst. 81(22):1989;1739-1743.
23. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., Blum R.H., Green M.D., Mason B. et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 7:1989;1602-1613.
24. Clamon G., Herndon J., Perry M.C., Ozer H., Kreisman H., Maher T. et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a Phase II trial of Cancer and Leukemia Group B. J. Natl. Cancer Inst. 85(4):1993;316-320.
25. Cellerino R., Tummarello D., Graziano F., Santo A., Pasini F., Isidori P. et al. Advanced non-small cell lung cancer: Phase II study with rIL-2 and alpha-IFN in patients responsive or stable to induction chemotherapy (meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 12:1993;A1169.
26. Schiller J.H., Morgan-Ihrig C., Levitt M.L. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 18(1):1995;47-51.